Add Yahoo as a preferred source to see more of our stories on Google. Oncologists at the world's largest cancer conference gave a standing ovation after data showed a pancreatic cancer drug nearly ...

A cancer drug receiving a standing ovation from a packed auditorium full of oncologists is not a routine event. When Dr. Brian Wolpin of Dana-Farber Cancer Institute advanced to a single slide at the ...

PETALING JAYA: A new pancreatic cancer drug has generated unusual excitement among cancer specialists, after clinical trial results showed it could significantly extend survival in patients with one ...

Three phase III trial results presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago this weekend delivered what oncologists are already calling the most consequential ...

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...